ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Primary care

Oxycodone Capsules Put on Hold; Clinical Trials for Lupus Nephritis & SLE Therapies

Michele B. Kaufman, PharmD, BCGP  |  November 25, 2015

Due to a lawsuit, the FDA has issued only tentative approval for an extended-release oxycodone capsule. Obinutuzumab is in clinical trials for lupus nephritis, and subcutaneous belimumab is being tested for SLE…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:belimumabLupus nephritisobinutuzumabOxycodoneSLEsystemic lupus erythematosus (SLE)

Rheumatology Research Foundation Scholarships Help Students Attend ACR/ARHP Annual Meeting

Thomas R. Collins  |  November 17, 2015

Seven students pursuing rheumatology-related careers will head to San Francisco in November on a Student and Resident ACR/ARHP Annual Meeting Scholarship—awards that are open to students and residents from states that are underserved by rheumatology professionals. The Rheumatology Research Foundation has awarded the students $750–1,500 toward travel expenses and registration for the ACR/ARHP Annual Meeting,…

Filed under:Career DevelopmentEducation & TrainingProfessional TopicsResearch Rheum Tagged with:ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)medical studentsresidentsRheumatology Research FoundationSan FranciscoScholarship

Health Video Games Spark Interest, Try to Gain Traction

Thomas R. Collins  |  November 16, 2015

In the late 1990s, Thomas Baranowski, PhD, professor of pediatrics specializing in nutrition at the Baylor College of Medicine, Houston, applied for a grant. For years, he had been interested in finding ways to get children to change their diet and physical activity. He decided to try a video game, and he got the money…

Filed under:AppsTechnology Tagged with:appsExercisehealthmobileOutcomespatient carephysical fitnessTechnology

Diagnostic Criteria Released for Neuromyelitis Optica Spectrum Disorders

Mary Beth Nierengarten  |  November 16, 2015

Recent updates to criteria used for diagnosing neuromyelitis optica (NMO) are aimed at helping physicians make the differential diagnosis of this disorder differentiating it from other inflammatory disorders—a diagnosis that can be difficult given the presenting symptoms that can mimic a number of other conditions, such as multiple sclerosis. Published in July 2015, the new…

Filed under:ConditionsPractice Support Tagged with:AC&RAmerican College of Rheumatology (ACR)criteriaDiagnosisGuidelinesneuromyelitis optica spectrumrheumatology

Tofacitinib on Hold for Psoriasis, Plus Anti-TNFs Top FDA List for Adverse Events

Michele B. Kaufman, PharmD, BCGP  |  October 28, 2015

The FDA is asking for more safety analysis before approving tofacitinib to treat psoriasis. Also, adalimumab and etanercept received the greatest number of adverse and serious adverse events reported to the FDA in 2014…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabadverse eventsAnti-TNFetanerceptFDAFood and Drug AdministrationInstitute for Safe Medication Practicesplaque psoriasisTofacitinibtofacitinib citrate

Opinion: Insurance Companies Use Medically and Fiscally Irresponsible Formularies

Bruce Rothschild, MD  |  October 14, 2015

Receipt of an unsolicited communication that a sweepstakes award has been won may con some people (especially, but not limited to, those underprivileged or undereducated as to legalities), but can’t fool all of the people all of the time. The names of the organizations and products involved are often marketing tool inventions, which imply special…

Filed under:EthicsInsuranceLegal UpdatesProfessional Topics Tagged with:formulariesinsuranceLegalrheumatology

Documentation: A Key Factor of Risk Adjustment

From the College  |  October 14, 2015

In an age of constant change and regulations, one thing remains the same in coding and billing: If it’s not documented, it wasn’t done. This is the main rule for documentation. Good documentation is and always has been the foundation of accurately capturing a provider’s work and the patient’s condition, management and treatment. Introduced by…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCodingDocumentationICD-10Practice Managementrheumatologist

Ethics Forum: Personal Ethics Questions Surrounding RheumPAC Donations

Matthew L. Mundwiler, MD, & Robert H. Shmerling, MD  |  October 14, 2015

Imagine you’ve just heard a compelling presentation urging all ACR members to contribute to RheumPAC, the ACR’s political action committee. RheumPAC’s mission is to support politicians who support issues important to rheumatologists. You are impressed by the role RheumPAC has played in a number of issues you support. Just as you’re writing a check, you…

Filed under:EthicsLegislation & AdvocacyProfessional Topics Tagged with:AdvocacydonationsEthicsLegislationPoliticsrheumatologistsrheumatologyRheumPAC

Tabalumab Modestly Effective in Systemic Lupus Erythematosus

Will Boggs, MD  |  October 7, 2015

NEW YORK (Reuters Health)—Tabalumab, a monoclonal antibody to B-cell activating factor, was modestly better than placebo in relieving symptoms of systemic lupus erythematosus (SLE), according to results from the ILLUMINATE-2 trial. “Lupus is a complicated disease that does not behave the same way in all patients who share the clinical symptoms,” Dr. Joan T. Merrill…

Filed under:ConditionsDrug UpdatesSystemic Lupus Erythematosus Tagged with:B cellsSLEsystemic lupus erythematosus (SLE)tabalumab

Smartphone Apps Make Virtual House Calls

Kurt Ullman  |  September 29, 2015

Telemedicine apps used on mobile devices may help rheumatologists connect with select patients, increasing practice efficiency and patient access to treatment…

Filed under:AppsPractice SupportTechnology Tagged with:appointmentsappsmobile apppatient accesspatient caretelemedicine

  • « Previous Page
  • 1
  • …
  • 115
  • 116
  • 117
  • 118
  • 119
  • …
  • 139
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences